Literature DB >> 15504877

Altered susceptibility of Candida glabrata bloodstream isolates to triazoles at clinically relevant pH values: comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest methods.

Manjunath P Pai1, Ariel L Jones.   

Abstract

We studied the MICs of triazoles against 15 Candida glabrata clinical isolates by the NCCLS M27-A2, Sensititre YeastOne, and Etest methods by using media at pHs 6.0, 7.0, and 7.4. Thirteen isolates were less susceptible to triazoles at pH 6.0 and more susceptible to triazoles at pH 7.4 compared to pH 7.0.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15504877      PMCID： PMC525437          DOI： 10.1128/AAC.48.11.4441-4443.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Influence of pH and concentration on the postantifungal effect and on the effects of sub-MIC concentrations of 4 antifungal agents on previously treated Candida spp.

Authors:  M T García; M T Llorente; F Mínguez; J Prieto
Journal:  Scand J Infect Dis       Date:  2000

3.  Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts.

Authors:  I Gadea; M Cuenca; M I Gegúndez; J Zapardiel; M L Valero; F Soriano
Journal:  J Antimicrob Chemother       Date:  1997-04       Impact factor: 5.790

4.  The trailing end point phenotype in antifungal susceptibility testing is pH dependent.

Authors:  K A Marr; T R Rustad; J H Rex; T C White
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.

Authors:  Anne Favel; Annie Michel-Nguyen; Annick Datry; Svetlana Challier; Florence Leclerc; Christiane Chastin; Karim Fallague; Patrick Regli
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790
  6 in total
  5 in total

1.  Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Authors:  Vladimír Hrabovský; Victoria Takáčová; Eva Schréterová; Lydia Pastvová; Zuzana Hrabovská; Katarina Čurová; Leonard Siegfried
Journal:  Folia Microbiol (Praha)       Date:  2017-03-30       Impact factor: 2.099

2.  Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys.

Authors:  Alexandra Vallon-Eberhard; Arik Makovitzki; Anne Beauvais; Jean-Paul Latgé; Steffen Jung; Yechiel Shai
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

3.  pH-Dependant Antifungal Activity of Valproic Acid against the Human Fungal Pathogen Candida albicans.

Authors:  Julien Chaillot; Faiza Tebbji; Carlos García; Hugo Wurtele; René Pelletier; Adnane Sellam
Journal:  Front Microbiol       Date:  2017-10-09       Impact factor: 5.640

4.  In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis.

Authors:  Jack D Sobel; Katyna Borroto-Esoda; Nkechi Azie; David Angulo
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

5.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.